Will Medicare Pay for Weight Loss Drugs? (2026)

Direct Answer: Will Medicare Pay for Weight Loss Drugs?

It depends. Original Medicare Part D has excluded drugs prescribed solely for weight loss since the program began, and Medigap and Part A/B alone never cover any prescription drugs. Part D already covers GLP-1 drugs like Ozempic, Wegovy, and Zepbound when prescribed for diabetes, cardiovascular risk reduction, or sleep apnea. A temporary CMS demonstration, the Medicare GLP-1 Bridge, began July 1, 2026, adding a $50 monthly copay for three obesity-indication GLP-1 products through December 31, 2027.

The Federal Exclusion Behind the 'It Depends'

Congress created Medicare Part D through the Medicare Modernization Act of 2003, and the same law carved anti-obesity agents out of the drug benefit from the start. That carve-out lives in Social Security Act Section 1927(d)(2)(A), and it is a categorical statutory exclusion, not a plan-level decision a formulary committee can override. Original Medicare Part A and Part B never covered self-administered outpatient drugs in the first place, so weight-loss pills and injections were never on the table there either.

Medicare beneficiaries writing a prescription with an obesity-only diagnosis code, even for a well-known brand like Wegovy or Zepbound, still hit the exclusion in 2026 unless one of the two carve-outs described below applies. No amount of appealing changes that outcome when the diagnosis is weight loss alone, because the block is written into federal law rather than into any individual plan's rules.

What Part D Already Covers: Diabetes, Heart Risk, and Sleep Apnea

Ozempic and Mounjaro carry FDA approval for type 2 diabetes, so Part D and Medicare Advantage drug plans can and do cover them for beneficiaries with a diabetes diagnosis, at standard Part D cost-sharing. The FDA expanded Wegovy's label on March 8, 2024, to reduce major cardiovascular events in adults with established heart disease and overweight or obesity, and CMS confirmed that indication sits outside the anti-obesity exclusion. Zepbound picked up a third pathway in December 2024, when the FDA approved it for moderate-to-severe obstructive sleep apnea in adults with obesity.

Rybelsus, the oral form of semaglutide, follows the diabetes rule the same way Ozempic does. In every one of these cases, coverage hinges entirely on the diagnosis code the prescriber submits, not on the brand name; the same molecule can be covered or denied depending on whether the paperwork says diabetes, cardiovascular risk reduction, sleep apnea, or weight loss.

The Medicare GLP-1 Bridge: $50 a Month Starting July 2026

CMS launched the Medicare GLP-1 Bridge on July 1, 2026, a nationwide demonstration that pays for weight-management GLP-1 drugs outside the diabetes, heart-disease, or sleep-apnea pathways. Eligible enrollees age 18 and older pay a flat $50 pharmacy copay for a one-month supply of Foundayo (tablet), Wegovy (injection or tablet), or Zepbound in the KwikPen formulation only; single-dose Zepbound pens and vials are not included. CMS initially planned the pilot to end December 31, 2026, but extended it through December 31, 2027 after the related BALANCE Model, a broader coverage expansion, was delayed indefinitely for 2027.

• Clinical eligibility: BMI of 35 or higher, OR BMI of 30 or higher with heart failure, uncontrolled hypertension, or advanced chronic kidney disease, OR BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease
• Not eligible for the Bridge: enrollees already receiving a GLP-1 through standard Part D coverage, or with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, since those groups already have a covered pathway
• Prescribers must submit a prior authorization, valid through December 31, 2027, and certify the prescription includes a lifestyle program covering diet and exercise
• The $50 copay applies whether the enrollee is in a standalone Part D plan, an MA-PD plan, a Special Needs Plan, or the Limited Income Newly Eligible Transition program

What Weight Loss Drugs Cost Without Medicare Coverage in 2026

Wegovy lists at roughly $1,349 a month and Zepbound at roughly $1,059 a month in 2026 for beneficiaries who don't qualify for the diabetes, cardiovascular, sleep-apnea, or Bridge pathways. KFF polling found that 56% of GLP-1 users report the drugs are difficult to afford, with about one in four describing access as very difficult. Medigap plans never step in here, since supplement policies only reduce Part A and Part B cost-sharing and have no relationship to Part D drug pricing at all.

Medicare Advantage vs Original Medicare vs Medigap for This Benefit

Medicare Advantage plans that bundle drug coverage (MA-PD) follow the exact same statutory rules and Bridge eligibility as standalone Part D plans, so switching to Medicare Advantage does not unlock weight-loss drug coverage on its own. Some MA-PD plans layer on unrelated supplemental benefits, such as a dietitian visit allowance or a $0 gym membership, but those extras never change whether the drug itself is covered; the drug coverage decision always traces back to Part D's diagnosis-code rules.

Original Medicare enrollees who pair Part A and Part B with a standalone Part D plan get identical drug-coverage rules to Medicare Advantage enrollees; the only structural difference is who administers the benefit. Medigap, by contrast, never touches drug costs under any circumstance, so a Medigap policy is irrelevant to this specific coverage question regardless of plan letter or premium.

Alternatives If You Don't Qualify for the Bridge or an Approved Indication

Dual-eligible beneficiaries enrolled in both Medicare and Medicaid have another option, since state Medicaid drug formularies are not bound by the Part D anti-obesity exclusion; several states already cover Wegovy or Zepbound for obesity management at Medicaid's own cost-sharing rates, often $0 to $4 per prescription. Beneficiaries with low income can apply for the Part D Extra Help (Low-Income Subsidy) program, which lowers premiums and standard cost-sharing on covered drugs, though it does not apply to the flat Bridge copay.

Manufacturer savings cards from Novo Nordisk and Eli Lilly are generally off-limits once a patient is enrolled in Medicare, because federal law bars using commercial copay coupons alongside a federal health program. Beneficiaries under 65 who are not yet Medicare-eligible, such as those on a spouse's plan or an early-retirement bridge, may find broader access through an ACA-compliant marketplace plan; essential health benefit rules vary by state, and a marketplace plan cannot deny enrollment or raise premiums based on a preexisting condition like obesity, unlike the individual market before 2014. Telehealth clinics offering compounded semaglutide or tirzepatide have shrunk sharply since the FDA resolved the branded-drug shortage in 2025 and restricted mass compounding, so beneficiaries should confirm any compounded product is dispensed by a licensed pharmacy under an individual prescription, not a mass-produced substitute.

Does Medicare cover Wegovy in 2026?

Yes, in two situations. Part D covers Wegovy when a doctor prescribes it to reduce cardiovascular risk in a beneficiary with established heart disease, an indication the FDA approved in March 2024. Beneficiaries who don't have heart disease but meet BMI and comorbidity criteria can get Wegovy through the Medicare GLP-1 Bridge for a $50 monthly copay starting July 1, 2026. Outside both paths, Wegovy costs about $1,349 a month out of pocket.

Does Medicare cover Ozempic for weight loss?

Not for weight loss specifically. Ozempic carries an FDA indication for type 2 diabetes only, so Medicare Part D can cover it when a beneficiary has a diabetes diagnosis, but it is not on the Medicare GLP-1 Bridge's covered-drug list and cannot be prescribed for weight loss alone under any 2026 exception. Wegovy, a higher-dose semaglutide with a weight-management indication, is the version that qualifies for the Bridge.

What is the Medicare GLP-1 Bridge program?

The Medicare GLP-1 Bridge is a temporary CMS demonstration that began July 1, 2026, and runs through December 31, 2027. It covers Foundayo, Wegovy, and Zepbound KwikPen for chronic weight management at a flat $50 monthly copay for enrollees who meet BMI and comorbidity criteria, regardless of whether they have diabetes or heart disease. The copay doesn't count toward the 2026 Part D out-of-pocket cap of $2,100.

Does Medicare Advantage cover weight loss drugs differently than Part D?

No, not for the drug itself. Medicare Advantage plans that include drug coverage (MA-PD) follow the identical Part D statutory rules and the same Bridge eligibility criteria as standalone Part D plans. Some MA-PD plans add unrelated supplemental benefits, like a nutrition counseling allowance or a fitness membership, but those extras never change whether a specific weight-loss drug is covered under Part D's diagnosis-code rules.

Does Medigap help pay for weight loss drugs?

No. Medigap policies only reduce out-of-pocket costs for Part A and Part B services, such as hospital coinsurance and the Part B deductible. Medigap has never covered prescription drugs of any kind since Congress removed drug benefits from new Medigap plans in 2006, so a Medigap policy has zero effect on weight-loss drug coverage or cost, regardless of plan letter.

How much do weight loss drugs cost without Medicare coverage in 2026?

Wegovy lists at roughly $1,349 a month and Zepbound at roughly $1,059 a month in 2026 for beneficiaries who don't qualify under the diabetes, cardiovascular, sleep-apnea, or Bridge pathways. Manufacturer savings cards from Novo Nordisk and Eli Lilly generally cannot be combined with any Medicare coverage, so cash-pay Medicare beneficiaries typically face the full list price at the pharmacy counter.

What happens to weight-loss drug coverage after the Bridge program ends?

The Bridge is scheduled to expire December 31, 2027. After that date, the statutory anti-obesity exclusion in Section 1927(d)(2)(A) of the Social Security Act reasserts itself unless Congress amends the law before then. A related, broader coverage expansion called the BALANCE Model was delayed indefinitely for Medicare in 2027, so beneficiaries should not assume permanent coverage and should monitor medicare.gov for updates.

Can I get weight loss drugs covered if I have both Medicare and Medicaid?

Possibly, and often more easily than through Medicare alone. State Medicaid drug formularies are not bound by the Part D anti-obesity exclusion, and several states already cover Wegovy or Zepbound for obesity management at low Medicaid cost-sharing, often $0 to $4 per prescription. Check with your state Medicaid agency or use an eligibility screener to see whether your income qualifies for dual-eligible status.